אודות פרק זה
Elliot Hershberg is a partner at Amplify Partners and author of the popular blog Century of Biology. In this episode, we talk about GLP-1s as a breakthrough moment for biotech, why drug development is starting to behave like software, and how falling discovery costs could finally free biotech startups from selling themselves to pharma.
We also talk about Elliot’s "massive markets, medium prices" thesis, the rise of consumer and "n-of-one" medicine, and Sid Sijbrandij going founder mode on his cancer by measuring himself, using AI to build a pipeline of personalized therapies, and is now disease-free.
Thank you to SynBioBeta for hosting us at their conference, where we recorded this episode, and several others we’ll be releasing soon!
Check out Elliot's blog at centuryofbio.com
